Navigation Links
MIT's Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
Date:4/6/2011

INDIANAPOLIS, April 6,  2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the David H. Koch Institute for Integrative Cancer Research at MIT will be using the Roche LightCycler® 480 System, a real-time polymerase chain reaction (PCR) system for the analysis of gene expression and genetic variation, in advanced cancer research.

The Koch Institute plans to use the LightCycler 480 System to support several key areas of research it has identified as being critical for rapid progress toward controlling cancer, such as exploring the molecular and cellular basis of metastasis and engineering the immune system to fight cancer.  The Institute is affiliated with the Massachusetts Institute of Technology in Cambridge, Mass.

"Our approach at MIT offers a unique collaboration between scientists and engineers, which has helped place us at the forefront of the fight against cancer," said Robert Urban, executive director of the Koch Institute. "The LightCycler instruments will provide the platform to help us take advantage of the many applications for real-time PCR technology in cancer research."

The LightCycler 480 System is a fully integrated, 96-well and 384-well plate-based real-time PCR platform for the qualitative and quantitative detection of nucleic acids. It can be used in a broad range of applications in research fields, such as gene expression studies, discovery and analysis of genetic variation, or array data validation. More information is available at www.roche-applied-science.com.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

The LightCycler 480 System is for use in life science research only. Not for use in diagnostic procedures.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact: Betsy Cox Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN(317) 521-3911betsy.cox@roche.com
'/>"/>

SOURCE Roche Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Submits 510(k) Application to FDA for Symbiq™ Infusion System Modifications
2. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
3. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
4. Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. CardioVascular BioTherapeutics Submits FDA Application for Fast Track Status for CVBT-141B, CVBTs Biological Treatment for Diabetes Patients
7. FDA Limits Acetaminophen in Prescription Combination Products; Requires Liver Toxicity Warnings
8. Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication
9. Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older
10. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
11. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) today announced ... Aug. 7, 2017. ... and will serve as president emeritus during a planned, 90-day ... multiple leadership roles since he joined Diplomat with the acquisition ... decisive, strategic leadership which continues to benefit our patients and ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... When Amy Cowperthwait left ... she took with her a dream to make nursing education more relevant and prepare ... communication skills were integrated into healthcare provider education. , “The human element ...
(Date:8/17/2017)... ... August 17, 2017 , ... The line-up includes voices from all ... grow a dental practice in a competitive market environment where Corporate Dentistry is making ... just transform you and your practice.” says Daniel A. ‘Danny’ Bobrow, AIM Dental Marketing’s ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... distinguishes herself once more by being among Houston’s first plastic surgeons to offer ... quality plastic surgery care without disrupting busy schedules and maintaining the utmost discretion ...
(Date:8/17/2017)... ... 17, 2017 , ... Florida Hospital Zephyrhills showcased its newly ... The newly renovated ER was designed with patients in mind and offers: 24 ... to deliver patient results, improve efficiencies and reduce length of stay, two pirate-themed ...
(Date:8/17/2017)... ... , ... With the introduction of new devices, new features, and updates to ... smartwatch market. As of June 2017, nearly nine percent of U.S. consumers aged 18+ ... according to latest WEAR Report Industry Overview and Forecast from NPD’s Connected Intelligence, growth ...
Breaking Medicine News(10 mins):